Therapy Areas: Vaccines
NIH study indicates J&J COVID-19 shot gets better boost from Moderna or Pfizer vaccine
14 October 2021 -

A study run by the US National Institutes of Health (NIH) has suggested that people who were given Johnson & Johnson Inc's (NYSE:JNJ) COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc (NYSE:PFE)/BioNTech SE (Nasdaq:BNTX) or Moderna Inc (Nasdaq:MRNA), Reuters news agency reported on Thursday.

This preliminary study, which hasn't yet been peer reviewed, included over 450 adults who received initial shots from Pfizer, Moderna or Johnson & Johnson and showed that "mixing and matching" booster shots of different types is safe in adults.

Moderna's and Pfizer's vaccines are based on messenger RNA while J&J's uses viral vector technology.

The NIH study also contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.

Findings showed that mixing and matching doses for a booster produced similar side effects to those seen in primary vaccinations and raised no significant safety concerns.